<H1>Chapter DOI: 10.1208/aapsj070112<br/>Cited-By Count: 162</H1><table border="1" width="30%"><tr><td>Total References</td><td>140</td></tr><tr><td>Springer references</td><td>2</td></tr><tr><td>Non Springer references</td><td>138</td></tr><tr><td>BibStructured Count</td><td width="10%">140</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>94</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>5</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>5</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>5</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>5</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomies to mechanism.<Emphasis Type="Italic">Oncogene.</Emphasis> 2003;22:7468&#8211;7485.</td><td><a href=http://dx.doi.org/10.1038/sj.onc.1206948>10.1038/sj.onc.1206948</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Haimeur A, Conseil G, Deeley RG, Cole SP. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation.<Emphasis Type="Italic">Curr Drug Metab.</Emphasis> 2004;5:21&#8211;53.</td><td><a href=http://dx.doi.org/10.2174/1389200043489199>10.2174/1389200043489199</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1998;95:15665&#8211;15670.</td><td><a href=http://dx.doi.org/10.1073/pnas.95.26.15665>10.1073/pnas.95.26.15665</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Miyake K, Mickley L, Litman T, et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone resistant cells: demonstration of homology to ABC transport genes.<Emphasis Type="Italic">Cancer Res.</Emphasis> 1999;59:8&#8211;13.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.<Emphasis Type="Italic">Cancer Res.</Emphasis> 1998;58:5337&#8211;5339.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Rocchi E, Khodjakov A, Volk EL, et al. The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane.<Emphasis Type="Italic">Biochem Biophys Res Commun.</Emphasis> 2000;271:42&#8211;46.</td><td><a href=http://dx.doi.org/10.1006/bbrc.2000.2590>10.1006/bbrc.2000.2590</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.<Emphasis Type="Italic">Cancer Res.</Emphasis> 2001;61:3458&#8211;3464.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Allen JD, Schinkel AH. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2).<Emphasis Type="Italic">Mol Cancer Ther.</Emphasis> 2002;1:427&#8211;434.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).<Emphasis Type="Italic">Oncogene.</Emphasis> 2003;22:7340&#8211;7358.</td><td><a href=http://dx.doi.org/10.1038/sj.onc.1206938>10.1038/sj.onc.1206938</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Bates SE, Robey R, Miyake K, Rao K, Ross DD, Litman T. The role of half-transporters in multidrug resistance.<Emphasis Type="Italic">J Bioenerg Biomembr.</Emphasis> 2001;33:503&#8211;511.</td><td><a href=http://dx.doi.org/10.1023/A:1012879205914>10.1023/A:1012879205914</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Dean M, Allikmets R. Complete characterization of the human ABC gene family.<Emphasis Type="Italic">J Bioenerg Biomembr.</Emphasis> 2001;33:475&#8211;479.</td><td><a href=http://dx.doi.org/10.1023/A:1012823120935>10.1023/A:1012823120935</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Borst P, Elferink RO. Mammalian ABC transporters in health and disease.<Emphasis Type="Italic">Annu Rev Biochem.</Emphasis> 2002;71:537&#8211;592.</td><td><a href=http://dx.doi.org/10.1146/annurev.biochem.71.102301.093055>10.1146/annurev.biochem.71.102301.093055</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Riordan JR. Cystic fibrosis as a disease of misprocessing of the cystic fibrosis transmembrane conductance regulator glycoprotein.<Emphasis Type="Italic">Am J Hum Genet.</Emphasis> 1999;64:1499&#8211;1504.</td><td><a href=http://dx.doi.org/10.1086/302429>10.1086/302429</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Arnell H, Mantyjarvi M, Tuppurainen K, Andreasson S, Dahl N. Stargardt disease: linkage to the ABCR gene region on lp21-p22 in Scandinavian families.<Emphasis Type="Italic">Acta Ophthalmol Scand.</Emphasis> 1998;76:649&#8211;652.</td><td><a href=http://dx.doi.org/10.1034/j.1600-0420.1998.760602.x>10.1034/j.1600-0420.1998.760602.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Kartenbeck J, Leuschner U, Mayer R, Keppler D. Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome.<Emphasis Type="Italic">Hepatology.</Emphasis> 1996;23:1061&#8211;1066.</td><td><a href=http://dx.doi.org/10.1053/jhep.1996.v23.pm0008621134>10.1053/jhep.1996.v23.pm0008621134</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, Author_FamilyName_1, ArticleTitle, JournalTitle, FirstPage, VolumeID</td><td>CrossRef</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Klucken J, Buchler C, Orso E, et al. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport.<Emphasis Type="Italic">Proc Natl Acad Sci USA.</Emphasis> 2000;97:817&#8211;822.</td><td><a href=http://dx.doi.org/10.1073/pnas.97.2.817>10.1073/pnas.97.2.817</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Yu L, von Bergmann K, Lutjohann D, Hobbs HH, Cohen JC. Selective sterol accumulation in ABCG5/ABCG8-deficient mice.<Emphasis Type="Italic">J Lipid Res.</Emphasis> 2004;45:301&#8211;307.</td><td><a href=http://dx.doi.org/10.1194/jlr.M300377-JLR200>10.1194/jlr.M300377-JLR200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Graf GA, Yu L, Li WP, et al. ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion.<Emphasis Type="Italic">J Biol Chem.</Emphasis> 2003;278:48275&#8211;48282.</td><td><a href=http://dx.doi.org/10.1074/jbc.M310223200>10.1074/jbc.M310223200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Yu L, Li-Hawkins J, Hammer RE, et al. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol.<Emphasis Type="Italic">J Clin Invest.</Emphasis> 2002;110:671&#8211;680.</td><td><a href=http://dx.doi.org/10.1172/JCI200216001>10.1172/JCI200216001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Xu J, Liu Y, Yang Y, Bates S, Zhang JT. Characterization of oligomeric human half ABC transporter ABCG2/BCRP/MXR/ABCP in plasma membranes.<Emphasis Type="Italic">J Biol Chem.</Emphasis> 2004;279:19781&#8211;19789.</td><td><a href=http://dx.doi.org/10.1074/jbc.M310785200>10.1074/jbc.M310785200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Ozvegy C, Varadi A, Sarkadi B. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.<Emphasis Type="Italic">J Biol Chem.</Emphasis> 2002;277:47980&#8211;47990.</td><td><a href=http://dx.doi.org/10.1074/jbc.M207857200>10.1074/jbc.M207857200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Janvilisri T, Venter H, Shahi S, Reuter G, Balakrishnan L, van Veen HW Sterol transport by the human breast cancer resistance protein (ABC G2) expressed in Lactococcus lactis.<Emphasis Type="Italic">J Biol Chem.</Emphasis> 2003;278:20645&#8211;20651.</td><td><a href=http://dx.doi.org/10.1074/jbc.M301358200>10.1074/jbc.M301358200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Ross DD, Yang W, Abruzzo LV, et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.<Emphasis Type="Italic">J Natl Cancer Inst.</Emphasis> 1999;91:429&#8211;433.</td><td><a href=http://dx.doi.org/10.1093/jnci/91.5.429>10.1093/jnci/91.5.429</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Maliepaard M, van Gastelen MA, de Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.<Emphasis Type="Italic">Cancer Res.</Emphasis> 1999;59:4559&#8211;4563.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Yang CH, Schneider E, Kuo ML, Volk EL, Rocchi E, Chen YC. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells.<Emphasis Type="Italic">Biochem Pharmacol.</Emphasis> 2000;60:831&#8211;837.</td><td><a href=http://dx.doi.org/10.1016/S0006-2952(00)00396-8>10.1016/S0006-2952(00)00396-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26</td><td>BibArticle</td><td>Ishii M, Iwahana M, Mitsui I, et al. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variantsderived from the human lung cancer cell line PC-6.<Emphasis Type="Italic">Anticancer Drugs.</Emphasis> 2000;11:353&#8211;362.</td><td><a href=http://dx.doi.org/10.1097/00001813-200006000-00005>10.1097/00001813-200006000-00005</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27</td><td>BibArticle</td><td>Robey RW, Medina-Perez WY, Nishiyama K, et al. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BC rp/ABCP1), in flavopiridol-resistant human breast cancer cells.<Emphasis Type="Italic">Clin Cancer Res.</Emphasis> 2001;7:145&#8211;152.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR28</td><td>BibArticle</td><td>Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. The mouse Berpl/Mxr/Abep gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.<Emphasis Type="Italic">Cancer Res.</Emphasis> 1999;59:4237&#8211;4241.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR29</td><td>BibArticle</td><td>Eisenblatter T, Galla HJ. A new multidrug resistance protein at the blood-brain barrier.<Emphasis Type="Italic">Biochem Biophys Res Commun.</Emphasis> 2002;293:1273&#8211;1278.</td><td><a href=http://dx.doi.org/10.1016/S0006-291X(02)00376-5>10.1016/S0006-291X(02)00376-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30</td><td>BibArticle</td><td>Eisenblatter T, Huwel S, Galla HJ. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier.<Emphasis Type="Italic">Brain Res.</Emphasis> 2003;971:221&#8211;231.</td><td><a href=http://dx.doi.org/10.1016/S0006-8993(03)02401-6>10.1016/S0006-8993(03)02401-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31</td><td>BibArticle</td><td>Hori S, Ohtsuki S, Tachikawa M, et al. Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s).<Emphasis Type="Italic">J Neurochem.</Emphasis> 2004;90:526&#8211;536.</td><td><a href=http://dx.doi.org/10.1111/j.1471-4159.2004.02537.x>10.1111/j.1471-4159.2004.02537.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32</td><td>BibArticle</td><td>Rajagopal A, Simon SM. Subcellular localization and activity of multidrug resistance proteins.<Emphasis Type="Italic">Mol Biol Cell.</Emphasis> 2003;14:3389&#8211;3399.</td><td><a href=http://dx.doi.org/10.1091/mbc.E02-11-0704>10.1091/mbc.E02-11-0704</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33</td><td>BibArticle</td><td>Cole SP, Chanda ER, Dicke FP, Gerlach JH, Mirski SE. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.<Emphasis Type="Italic">Cancer Res.</Emphasis> 1991;51:3345&#8211;3352.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR34</td><td>BibArticle</td><td>Aust S, Obrist P, Jaeger W, et al. Subcellular localization of the ABCG2 transporter in normal and malignant human gallbladder epithelium.<Emphasis Type="Italic">Lab Invest.</Emphasis> 2004;84:1024&#8211;1036.</td><td><a href=http://dx.doi.org/10.1038/labinvest.3700127>10.1038/labinvest.3700127</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35</td><td>BibArticle</td><td>Litman T, Brangi M, Hudson E, et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2).<Emphasis Type="Italic">J Cell Sci.</Emphasis> 2000;113:2011&#8211;2021.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR36</td><td>BibArticle</td><td>Robey RW, Honjo Y, van de Laar A, et al. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2).<Emphasis Type="Italic">Biochim Biophys Acta.</Emphasis> 2001;1512:171&#8211;182.</td><td><a href=http://dx.doi.org/10.1016/S0005-2736(01)00308-X>10.1016/S0005-2736(01)00308-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37</td><td>BibArticle</td><td>Minderman H, Suvannasankha A, O'Loughlin KL, et al. Flow cytometric analysis of breast cancer resistance protein expression and function.<Emphasis Type="Italic">Cytometry.</Emphasis> 2002;48:59&#8211;65.</td><td><a href=http://dx.doi.org/10.1002/cyto.10111>10.1002/cyto.10111</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38</td><td>BibArticle</td><td>Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein.<Emphasis Type="Italic">Cancer Res.</Emphasis> 2000;60:47&#8211;50.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR39</td><td>BibArticle</td><td>Hazlehurst LA, Foley NE, Gleason-Guzman MC, et al. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line.<Emphasis Type="Italic">Cancer Res.</Emphasis> 1999;59:1021&#8211;1028.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR40</td><td>BibArticle</td><td>Nakagawa M, Schneider E, Dixon KH, et al. Reduced intracellular drug accumulation in the abscence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells.<Emphasis Type="Italic">Cancer Res.</Emphasis> 1992;52:6175&#8211;6181.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR41</td><td>BibArticle</td><td>Maliepaard M, van Gastelen MA, Tohgo A, et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.<Emphasis Type="Italic">Clin Cancer Res.</Emphasis> 2001;7:935&#8211;941.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR42</td><td>BibArticle</td><td>Kawabata S, Oka M, Shiozawa K, et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.<Emphasis Type="Italic">Biochem Biophys Res Commun.</Emphasis> 2001;280:1216&#8211;1223.</td><td><a href=http://dx.doi.org/10.1006/bbrc.2001.4267>10.1006/bbrc.2001.4267</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43</td><td>BibArticle</td><td>Nakatomi K, Yoshikawa M, Oka M, et al. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells.<Emphasis Type="Italic">Biochem Biophys Res Commun.</Emphasis> 2001;288:827&#8211;832.</td><td><a href=http://dx.doi.org/10.1006/bbrc.2001.5850>10.1006/bbrc.2001.5850</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44</td><td>BibArticle</td><td>Shiozawa K, Oka M, Soda H, et al. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.<Emphasis Type="Italic">Int J Cancer.</Emphasis> 2004;108:146&#8211;151.</td><td><a href=http://dx.doi.org/10.1002/ijc.11528>10.1002/ijc.11528</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR45</td><td>BibArticle</td><td>Rajendra R, Gounder MK, Saleem A, et al. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.<Emphasis Type="Italic">Cancer Res.</Emphasis> 2003;63:3228&#8211;3233.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR46</td><td>BibArticle</td><td>Bates SE, Medina-Perez WY, Kohlhagen G, et al. ABCG2 mediates differential resistance to SN-38 and homocamptothecins.<Emphasis Type="Italic">J Pharmacol Exp Ther.</Emphasis> 2004;310:836&#8211;842.</td><td><a href=http://dx.doi.org/10.1124/jpet.103.063149>10.1124/jpet.103.063149</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR47</td><td>BibArticle</td><td>Yoshikawa M, Ikegami Y, Hayasaka S, et al. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.<Emphasis Type="Italic">Int J Cancer.</Emphasis> 2004;110:921&#8211;927.</td><td><a href=http://dx.doi.org/10.1002/ijc.20216>10.1002/ijc.20216</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR48</td><td>BibArticle</td><td>Honjo Y, Hrycyna CA, Yan QW, et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.<Emphasis Type="Italic">Cancer Res.</Emphasis> 2001;61:6635&#8211;6639.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR49</td><td>BibArticle</td><td>Nakanishi T, Karp JE, Tan M, et al. Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients.<Emphasis Type="Italic">Clin Cancer Res.</Emphasis> 2003;9:3320&#8211;3328.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR50</td><td>BibArticle</td><td>Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance.<Emphasis Type="Italic">Cancer Res.</Emphasis> 2002;62:5035&#8211;5040.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR51</td><td>BibArticle</td><td>Chen Z-S, Robey RW, Belinsky MG, et al. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.<Emphasis Type="Italic">Cancer Res.</Emphasis> 2003;63:4048&#8211;4054.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR52</td><td>BibArticle</td><td>Robey RW, Honjo Y, Morisaki K, et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity.<Emphasis Type="Italic">Br J Cancer.</Emphasis> 2003;89:1971&#8211;1978.</td><td><a href=http://dx.doi.org/10.1038/sj.bjc.6601370>10.1038/sj.bjc.6601370</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR53</td><td>BibArticle</td><td>Miwa M, Tsukahara S, Ishikawa E, Asada S, Imai Y, Sugimoto Y. Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.<Emphasis Type="Italic">Int J Cancer.</Emphasis> 2003;107:757&#8211;763.</td><td><a href=http://dx.doi.org/10.1002/ijc.11484>10.1002/ijc.11484</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR54</td><td>BibArticle</td><td>Kim M, Turnquist H, Jackson J, et al. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.<Emphasis Type="Italic">Clin Cancer Res.</Emphasis> 2002;8:22&#8211;28.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR55</td><td>BibArticle</td><td>Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors.<Emphasis Type="Italic">Blood.</Emphasis> 2002;99:507&#8211;512.</td><td><a href=http://dx.doi.org/10.1182/blood.V99.2.507>10.1182/blood.V99.2.507</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR56</td><td>BibArticle</td><td>Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y. ABC G2 transports sulfated conjugates of steroids and xenobiotics.<Emphasis Type="Italic">J Biol Chem.</Emphasis> 2003;278:22644&#8211;22649.</td><td><a href=http://dx.doi.org/10.1074/jbc.M212399200>10.1074/jbc.M212399200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR57</td><td>BibArticle</td><td>Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y. Breast cancer resistance protein exports sulfated estrogens but not free estrogens.<Emphasis Type="Italic">Mol Pharmacol.</Emphasis> 2003;64:610&#8211;618.</td><td><a href=http://dx.doi.org/10.1124/mol.64.3.610>10.1124/mol.64.3.610</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR58</td><td>BibArticle</td><td>Ifergan I, Shafran A, Jansen G, Hooijberg JH, Scheffer GL, Assaraf YG. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression: Aa role for BCRP in cellular folate homeostasis.<Emphasis Type="Italic">J Biol Chem.</Emphasis> 2004;279:25527&#8211;25534.</td><td><a href=http://dx.doi.org/10.1074/jbc.M401725200>10.1074/jbc.M401725200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR59</td><td>BibArticle</td><td>Jonker JW, Buitelaar M, Wagenaar E, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria.<Emphasis Type="Italic">Proc Natl Acad Sci USA.</Emphasis> 2002;99:15449&#8211;15654.</td><td><a href=http://dx.doi.org/10.1073/pnas.202607599>10.1073/pnas.202607599</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR60</td><td>BibArticle</td><td>Robey RW, Steadman K, Polgar O, et al. Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition.<Emphasis Type="Italic">Cancer Res.</Emphasis> 2004;64:1242&#8211;1246.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-03-3298>10.1158/0008-5472.CAN-03-3298</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR61</td><td>BibArticle</td><td>Sinha R, Gustafson DR, Kulldorff M, Wen WQ, Cerhan JR, Zheng W. 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, a carcinogen in high-temperature-cooked meat, and breast cancer risk.<Emphasis Type="Italic">J Natl Cancer Inst.</Emphasis> 2000:92:1352&#8211;1354.</td><td><a href=http://dx.doi.org/10.1093/jnci/92.16.1352>10.1093/jnci/92.16.1352</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR62</td><td>BibArticle</td><td>van Herwaarden AE, Jonker JW, Wagenaar E, et al. The breast cancer resistance protein (Berpl/Abeg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.<Emphasis Type="Italic">Cancer Res.</Emphasis> 2003;63:6447&#8211;6452.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR63</td><td>BibArticle</td><td>Woehlecke H, Pohl A, Alder-Baerens N, Lage H, Herrmann A. Enhanced exposure of phosphatidylserine in human gastric carcinoma cells overexpressing the half-size ABC transporter BCRP (ABCG2).<Emphasis Type="Italic">Biochem J.</Emphasis> 2003;376:489&#8211;495.</td><td><a href=http://dx.doi.org/10.1042/BJ20030886>10.1042/BJ20030886</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR64</td><td>BibArticle</td><td>Erlichman C, Boerner SA, Hallgren CG, et al. The HER tyrosine kinase inhibitor C11033 enhances cytotoxicity of 7-ethyl-10-hydroxy-camptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.<Emphasis Type="Italic">Cancer Res.</Emphasis> 2001;61:739&#8211;748.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR65</td><td>BibArticle</td><td>Burger H, Van Tol H, Boersma AW, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.<Emphasis Type="Italic">Blood.</Emphasis> 2004;104:2940&#8211;2942.</td><td><a href=http://dx.doi.org/10.1182/blood-2004-04-1398>10.1182/blood-2004-04-1398</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR66</td><td>BibArticle</td><td>Imai Y, Tsukahara S, Asada S, Sugimoto Y. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.<Emphasis Type="Italic">Cancer Res.</Emphasis> 2004;64:4346&#8211;4352.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-04-0078>10.1158/0008-5472.CAN-04-0078</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR67</td><td>BibArticle</td><td>Polli JW, Baughman TM, Humphreys JE, et al. The systemic exposure of an N-methyl-d-aspartate receptor antagonist is limited in mice by the p-glycoprotein and breast cancer resistance protein efflux transporters.<Emphasis Type="Italic">Drug Metab Dispos.</Emphasis> 2004;32:722&#8211;726.</td><td><a href=http://dx.doi.org/10.1124/dmd.32.7.722>10.1124/dmd.32.7.722</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR68</td><td>BibArticle</td><td>Breedveld P, Zelcer N, Pluim D, et al. Mechanism of the pharmaco-kinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.<Emphasis Type="Italic">Cancer Res.</Emphasis> 2004;64:5804&#8211;5811.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-03-4062>10.1158/0008-5472.CAN-03-4062</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR69</td><td>BibArticle</td><td>Wang X, Furukawa T, Nitanda T, et al. Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.<Emphasis Type="Italic">Mol Pharmacol.</Emphasis> 2003;63:65&#8211;72.</td><td><a href=http://dx.doi.org/10.1124/mol.63.1.65>10.1124/mol.63.1.65</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR70</td><td>BibArticle</td><td>Wang X, Nitanda T, Shi M, et al. Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein.<Emphasis Type="Italic">Biochem Pharmacol.</Emphasis> 2004;68:1363&#8211;1370.</td><td><a href=http://dx.doi.org/10.1016/j.bcp.2004.05.052>10.1016/j.bcp.2004.05.052</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR71</td><td>BibArticle</td><td>Brangi M, Litman T, Ciotti M, et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.<Emphasis Type="Italic">Cancer Res.</Emphasis> 1999;59:5938&#8211;5946.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR72</td><td>BibArticle</td><td>Rabindran SK, He H, Singh M, et al. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C.<Emphasis Type="Italic">Cancer Res.</Emphasis> 1998;58:5850&#8211;5858.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR73</td><td>BibArticle</td><td>Sparreboom A, Gelderblom H, Marsh S, et al. Diflomotecan pharmacokinetics in relation to ABC G2 421C&gt;A genotype.<Emphasis Type="Italic">Clin Pharmacol Ther.</Emphasis> 2004;76:38&#8211;44.</td><td><a href=http://dx.doi.org/10.1016/j.clpt.2004.03.003>10.1016/j.clpt.2004.03.003</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR74</td><td>BibArticle</td><td>Volk EL, Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.<Emphasis Type="Italic">Cancer Res.</Emphasis> 2003;63:5538&#8211;5543.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR75</td><td>BibArticle</td><td>Nakagawa R, Hara Y, Arakawa H, Nishimura S, Komatani H. ABCG2 confers resistance to indolocarbazole compounds by ATP-dependent transport.<Emphasis Type="Italic">Biochem Biophys Res Commun.</Emphasis> 2002;299:669&#8211;675.</td><td><a href=http://dx.doi.org/10.1016/S0006-291X(02)02712-2>10.1016/S0006-291X(02)02712-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR76</td><td>BibArticle</td><td>Komatani H, Kotani H, Hara Y, et al. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.<Emphasis Type="Italic">Cancer Res.</Emphasis> 2001;61:2827&#8211;2832.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR77</td><td>BibArticle</td><td>de Bruin M, Miyake K, Litman T, Robey R, Bates SE. Reversal of resistance by GF120918 in cell lines expressing the ABC Half-transporter.<Emphasis Type="Italic">Cancer Lett.</Emphasis> 1999;146:117&#8211;126.</td><td><a href=http://dx.doi.org/10.1016/S0304-3835(99)00182-2>10.1016/S0304-3835(99)00182-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR78</td><td>BibArticle</td><td>Allen JD, van Loevezijn A, Lakhai JM, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.<Emphasis Type="Italic">Mol Cancer Ther.</Emphasis> 2002;1:417&#8211;425.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR79</td><td>BibArticle</td><td>van Loevezijn A, Allen JD, Schinkel AH, Koomen GJ. Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines.<Emphasis Type="Italic">Bioorg Med Chem Lett.</Emphasis> 2001;11:29&#8211;32.</td><td><a href=http://dx.doi.org/10.1016/S0960-894X(00)00588-6>10.1016/S0960-894X(00)00588-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR80</td><td>BibArticle</td><td>&#214;zvegy-Laczka C, Hegedus T, Varady G, et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.<Emphasis Type="Italic">Mol Pharmacol.</Emphasis> 2004;65:1485&#8211;1495.</td><td><a href=http://dx.doi.org/10.1124/mol.65.6.1485>10.1124/mol.65.6.1485</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR81</td><td>BibArticle</td><td>Houghton PJ, Germain GS, Harwood FC, et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.<Emphasis Type="Italic">Cancer Res</Emphasis>. 2004;64:2333&#8211;2337.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-03-3344>10.1158/0008-5472.CAN-03-3344</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR82</td><td>BibArticle</td><td>Yang CH, Chen YC, Kuo ML. Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone.<Emphasis Type="Italic">Anticancer Res</Emphasis>. 2003;23:2519&#8211;2523.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR83</td><td>BibArticle</td><td>Sugimoto Y, Tsukahara S, Imai Y, Ueda K, Tsuruo T. Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.<Emphasis Type="Italic">Mol Cancer Ther</Emphasis>. 2003;2:105&#8211;112.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR84</td><td>BibArticle</td><td>Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrpl/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype.<Emphasis Type="Italic">Nat Med</Emphasis>. 2001;7:1028&#8211;1034.</td><td><a href=http://dx.doi.org/10.1038/nm0901-1028>10.1038/nm0901-1028</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR85</td><td>BibArticle</td><td>Minderman H, O'Loughlin KL, Pendyala L, Baer MR. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.<Emphasis Type="Italic">Clin Cancer Res</Emphasis>. 2004;10:1826&#8211;1834.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-0914-3>10.1158/1078-0432.CCR-0914-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR86</td><td>BibArticle</td><td>Woehlecke H, Osada H, Herrmann A, Lage H. Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A.<Emphasis Type="Italic">Int J Cancer</Emphasis>. 2003;107:721&#8211;728.</td><td><a href=http://dx.doi.org/10.1002/ijc.11444>10.1002/ijc.11444</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR87</td><td>BibArticle</td><td>Zhang S, Yang X, Morris ME. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2).<Emphasis Type="Italic">Mol Pharmacol</Emphasis>. 2004;65:1208&#8211;1216.</td><td><a href=http://dx.doi.org/10.1124/mol.65.5.1208>10.1124/mol.65.5.1208</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR88</td><td>BibArticle</td><td>Cooray HC, Janvilisri T, van Veen HW, Hladky SB, Barrand MA. Interaction of the breast cancer resistance protein with plant polyphenols.<Emphasis Type="Italic">Biochem Biophys Res Commun</Emphasis>. 2004;317:269&#8211;275.</td><td><a href=http://dx.doi.org/10.1016/j.bbrc.2004.03.040>10.1016/j.bbrc.2004.03.040</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR89</td><td>BibArticle</td><td>Gupta A, Zhang Y, Unadkat JD, Mao Q. HiV Protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2004;310:334&#8211;341.</td><td><a href=http://dx.doi.org/10.1124/jpet.104.065342>10.1124/jpet.104.065342</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR90</td><td>BibArticle</td><td>Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH. Mouse breast cancer resistance protein (Berpl/Abeg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.<Emphasis Type="Italic">Cancer Res</Emphasis>. 2003;63:1339&#8211;1344.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR91</td><td>BibArticle</td><td>Kruijtzer CM, Beijnen JH, Rosing H, et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.<Emphasis Type="Italic">J Clin Oncol</Emphasis>. 2002;20:2943&#8211;2950.</td><td><a href=http://dx.doi.org/10.1200/JCO.2002.12.116>10.1200/JCO.2002.12.116</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR92</td><td>BibArticle</td><td>Jonker JW, Smit JW, Brinkhuis RF, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.<Emphasis Type="Italic">J Natl Cancer Inst.</Emphasis> 2000;92:1651&#8211;1656.</td><td><a href=http://dx.doi.org/10.1093/jnci/92.20.1651>10.1093/jnci/92.20.1651</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR93</td><td>BibArticle</td><td>Allen JD, Jackson SC, Schinkel AH. A mutation hot spot in the Berpl (Abcg2) multidrug transporter in mouse cell lines selected for doxorubicin resistance.<Emphasis Type="Italic">Cancer Res</Emphasis>. 2002;62:2294&#8211;2299.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR94</td><td>BibArticle</td><td>Alqawi O, Bates S, Georges E. Arginine 482 to threonine 482 mutation in breast cancer resistance protein (ABCG2) inhibits rhodaminel 23 transport while increasing binding.<Emphasis Type="Italic">Biochem J</Emphasis>. 2004;382:711&#8211;716.</td><td><a href=http://dx.doi.org/10.1042/BJ20040355>10.1042/BJ20040355</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR95</td><td>BibArticle</td><td>Zamber CP, Lamba JK, Yasuda K, et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.<Emphasis Type="Italic">Pharmacogenetics</Emphasis>. 2003;13:19&#8211;28.</td><td><a href=http://dx.doi.org/10.1097/00008571-200301000-00004>10.1097/00008571-200301000-00004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR96</td><td>BibArticle</td><td>Imai Y, Nakane M, Kage K, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.<Emphasis Type="Italic">Mol Cancer ther</Emphasis>. 2002;1:611&#8211;616.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR97</td><td>BibArticle</td><td>Honjo Y, Morisaki K, Huff LM. et al. Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1).<Emphasis Type="Italic">Cancer Biol Ther.</Emphasis> 2002;1:696&#8211;702.</td><td><a href=http://dx.doi.org/10.4161/cbt.322>10.4161/cbt.322</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, FirstPage, Author_FamilyName_2, ArticleTitle, Year, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR98</td><td>BibArticle</td><td>Mizuarai S, Aozasa N, Kotani H. Single nucleotide polymorphisms result, in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.<Emphasis Type="Italic">Int J Cancer</Emphasis>. 2004;109:238&#8211;246.</td><td><a href=http://dx.doi.org/10.1002/ijc.11669>10.1002/ijc.11669</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR99</td><td>BibArticle</td><td>Kage K, Tsukahara S, Sugiyama T, et al. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization.<Emphasis Type="Italic">Int J Cancer</Emphasis>, 2002;97:626&#8211;630.</td><td><a href=http://dx.doi.org/10.1002/ijc.10100>10.1002/ijc.10100</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR100</td><td>BibArticle</td><td>Litman T, Jensen U, Hansen A, et al. Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2.<Emphasis Type="Italic">Biochim Biophys Acta</Emphasis>. 2002;1565:6&#8211;16.</td><td><a href=http://dx.doi.org/10.1016/S0005-2736(02)00492-3>10.1016/S0005-2736(02)00492-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR101</td><td>BibArticle</td><td>Mao Q, Conseil G, Gupta A, Cole SP, Unadkat JD. Functional expression of the human breast cancer resistance protein in Pichia pastoris.<Emphasis Type="Italic">Biochem Biophys Res Commun</Emphasis>. 2004;320:730&#8211;737.</td><td><a href=http://dx.doi.org/10.1016/j.bbrc.2004.06.012>10.1016/j.bbrc.2004.06.012</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR102</td><td>BibArticle</td><td>Mitomo H, Kato R, Ito A, et al. A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport.<Emphasis Type="Italic">Biochem J</Emphasis>. 2003;373:767&#8211;774.</td><td><a href=http://dx.doi.org/10.1042/BJ20030150>10.1042/BJ20030150</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR103</td><td>BibArticle</td><td>Polgar O, Robey RW, Morisaki K, et al. Mutational analysis of ABCG2: role of the GXXXG motif.<Emphasis Type="Italic">Biochemistry</Emphasis>, 2004;43:9448&#8211;9456.</td><td><a href=http://dx.doi.org/10.1021/bi0497953>10.1021/bi0497953</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR104</td><td>BibArticle</td><td>Ozvegy C, Litman T, Szakacs G, et al. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells.<Emphasis Type="Italic">Biochem Biophys Res Commun</Emphasis>. 2001;285:111&#8211;117.</td><td><a href=http://dx.doi.org/10.1006/bbrc.2001.5130>10.1006/bbrc.2001.5130</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR105</td><td>BibArticle</td><td>Ross DD, Karp JE, Chen TT, Doyle LA. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia.<Emphasis Type="Italic">Blood</Emphasis>. 2000;96:365&#8211;368.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR106</td><td>BibArticle</td><td>Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, Sauerbrey A. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia.<Emphasis Type="Italic">Leukemia</Emphasis>, 2002;16:1443&#8211;1447.</td><td><a href=http://dx.doi.org/10.1038/sj.leu.2402541>10.1038/sj.leu.2402541</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR107</td><td>BibArticle</td><td>Plasschaert SL, Van Der Kolk DM, De Bont ES, Vellenga E, Kamps WA, De Vries EG. Breast cancer resistance protein (BCRP) in acute leukemia.<Emphasis Type="Italic">Leuk Lymphoma</Emphasis>. 2004;45:649&#8211;654.</td><td><a href=http://dx.doi.org/10.1080/10428190310001597928>10.1080/10428190310001597928</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR108</td><td>BibArticle</td><td>Abbott BL, Colapietro AM, Barnes Y, Marini F, Andreeff M, Sorrentino BP. Low levels of ABCG2 expression in adult AML blast samples.<Emphasis Type="Italic">Blood</Emphasis>. 2002;100:4594&#8211;4601.</td><td><a href=http://dx.doi.org/10.1182/blood-2002-01-0271>10.1182/blood-2002-01-0271</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR109</td><td>BibArticle</td><td>van der Kolk DM, Vellenga E, Scheffer GL, et al. Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia.<Emphasis Type="Italic">Blood</Emphasis>. 2002;99:3763&#8211;3770.</td><td><a href=http://dx.doi.org/10.1182/blood.V99.10.3763>10.1182/blood.V99.10.3763</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR110</td><td>BibArticle</td><td>Sauerbrey A, Sell W, Steinbach D, Voigt A, Zintl F. Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia.<Emphasis Type="Italic">Br J Haematol</Emphasis>. 2002;118:147&#8211;150.</td><td><a href=http://dx.doi.org/10.1046/j.1365-2141.2002.03550.x>10.1046/j.1365-2141.2002.03550.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR111</td><td>BibArticle</td><td>Plasschaert SL, van der Kolk DM, de Bont ES, et al. The role of breast cancer resistance protein in acute lymphoblastic leukemia.<Emphasis Type="Italic">Clin Cancer Res</Emphasis>. 2003;9:5171&#8211;5177.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR112</td><td>BibArticle</td><td>Ren JH, Du XY, Guo XN, et al. Relationship between resistance to chemotherapy and expression of breast cancer resistance protein (BCRP) gene in patients with acute leukemia.<Emphasis Type="Italic">Zhongguo Shi Yan Xue Ye Xue Za Zhi</Emphasis>. 2004;12:55&#8211;58.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR113</td><td>BibArticle</td><td>van der Pol MA, Broxterman HJ, Pater JM, et al. Function of the ABC transporters. P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia.<Emphasis Type="Italic">Haematologica</Emphasis>. 2003;88:134&#8211;147.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR114</td><td>BibArticle</td><td>van den Heuvel-Eibrink MM, Wiemer EA, Prins A, et al. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML).<Emphasis Type="Italic">Leukemia</Emphasis>. 2002;16:833&#8211;839.</td><td><a href=http://dx.doi.org/10.1038/sj.leu.2402496>10.1038/sj.leu.2402496</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR115</td><td>BibArticle</td><td>Sargent JM, Williamson CJ, Maliepaard M, Elgic AW, Scheper RJ, Taylor CG. Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia.<Emphasis Type="Italic">Br J Haematol</Emphasis>. 2001;115:257&#8211;262.</td><td><a href=http://dx.doi.org/10.1046/j.1365-2141.2001.03122.x>10.1046/j.1365-2141.2001.03122.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR116</td><td>BibArticle</td><td>Stam RW, van den Heuvel-Eibrink MM, den Boer ML, et al. Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein.<Emphasis Type="Italic">Leukemia</Emphasis>. 2004;18:78&#8211;83.</td><td><a href=http://dx.doi.org/10.1038/sj.leu.2403168>10.1038/sj.leu.2403168</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR117</td><td>BibArticle</td><td>Suvannasankha A, Minderman H, O'Loughlin KL, et al. Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function.<Emphasis Type="Italic">Leukemia</Emphasis>. 2004;18:1252&#8211;1257.</td><td><a href=http://dx.doi.org/10.1038/sj.leu.2403395>10.1038/sj.leu.2403395</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR118</td><td>BibArticle</td><td>Scheffer GL, Maliepaard M, Pijnenborg AC, et al. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone-and topotecan-resistant cell lines.<Emphasis Type="Italic">Cancer Res</Emphasis>. 2000;60:2589&#8211;2593.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR119</td><td>BibArticle</td><td>Diestra JE, Scheffer GL, Catala I, et al. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material.<Emphasis Type="Italic">J Pathol</Emphasis>. 2002;198:213&#8211;219.</td><td><a href=http://dx.doi.org/10.1002/path.1203>10.1002/path.1203</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR120</td><td>BibArticle</td><td>Kawabata S, Oka M, Soda H, et al. Expression and functional analyses of breast cancer resistance protein in lung cancer.<Emphasis Type="Italic">Clin Cancer Res.</Emphasis> 2003;9:3052&#8211;3057.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR121</td><td>BibArticle</td><td>Yoh K, Ishii G, Yokose T, et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer.<Emphasis Type="Italic">Clin Cancer Res</Emphasis>. 2004;10:1691&#8211;1697.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-0937-3>10.1158/1078-0432.CCR-0937-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR122</td><td>BibArticle</td><td>Candeil L, Gourdier I, Peyron D, et al.: ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.<Emphasis Type="Italic">Int J Cancer</Emphasis>. 2004;109:848&#8211;854.</td><td><a href=http://dx.doi.org/10.1002/ijc.20032>10.1002/ijc.20032</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR123</td><td>BibArticle</td><td>Kanzaki A, Toi M, Nakayama K, et al. Expression of multidrug resistance-related transporters in human breast carcinoma.<Emphasis Type="Italic">Jpn J Cancer Res</Emphasis>. 2001;92:452&#8211;458.</td><td><a href=http://dx.doi.org/10.1111/j.1349-7006.2001.tb01115.x>10.1111/j.1349-7006.2001.tb01115.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, VolumeID, Author_FamilyName_1, Year, Author_FamilyName_2, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR124</td><td>BibArticle</td><td>Faneyte IF, Kristel PM, Maliepaard M, et al. Expression of the breast cancer resistance protein in breast cancer.<Emphasis Type="Italic">Clin Cancer Res</Emphasis>. 2002;8:1068&#8211;1074.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR125</td><td>BibArticle</td><td>Burger H, Foekens JA, Look MP, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.<Emphasis Type="Italic">Clin Cancer Res</Emphasis>. 2003;9:827&#8211;836.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR126</td><td>BibArticle</td><td>Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD, Sorrentino BP. Berp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 2002;99:12339&#8211;12344.</td><td><a href=http://dx.doi.org/10.1073/pnas.192276999>10.1073/pnas.192276999</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR127</td><td>BibArticle</td><td>Tamaki T, Akatsuka A, Ando K, et al. Identification of myogenic-endothelial progenitor cells in the interstitial spaces of skeletal muscle.<Emphasis Type="Italic">J Cell Biol</Emphasis>. 2002;157:571&#8211;577.</td><td><a href=http://dx.doi.org/10.1083/jcb.200112106>10.1083/jcb.200112106</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR128</td><td>BibArticle</td><td>Leehner A, Leech CA, Abraham EJ, Nolan AL, Habener JF. Nestinpositive progenitor cells derived from adult human pancreatic islets of Langerhans contain side population (SP) cells defined by expression of the ABCG2 (BCRP1) ATP-binding cassette transporter.<Emphasis Type="Italic">Biochem Biophys Res Commun</Emphasis>. 2002;293:670&#8211;674.</td><td><a href=http://dx.doi.org/10.1016/S0006-291X(02)00275-9>10.1016/S0006-291X(02)00275-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR129</td><td>BibArticle</td><td>Shimano K, Satake M, Okaya A, et al. Hepatic oval cells have the side population phenotype defined by expression of ATP-binding cassette transporter ABCG2/BCRP1.<Emphasis Type="Italic">Am J Pathol</Emphasis>. 2003;163:3&#8211;9.</td><td><a href=http://dx.doi.org/10.1016/S0002-9440(10)63624-3>10.1016/S0002-9440(10)63624-3</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Year, ArticleTitle, Author_FamilyName_2, FirstPage, VolumeID</td><td>CrossRef</td></tr><tr><td>CR130</td><td>BibArticle</td><td>Martin CM, Meeson AP, Robertson SM, et al. Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart.<Emphasis Type="Italic">Dev Biol</Emphasis>. 2004;265:262&#8211;275.</td><td><a href=http://dx.doi.org/10.1016/j.ydbio.2003.09.028>10.1016/j.ydbio.2003.09.028</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR131</td><td>BibArticle</td><td>Krishnamurthy P, Ross DD, Nakanishi T, et al., The stem cell marker Berp/ABCG2 enhances hypoxic cell survival through interactions with heme.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 2004;279:24218&#8211;24225.</td><td><a href=http://dx.doi.org/10.1074/jbc.M313599200>10.1074/jbc.M313599200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR132</td><td>BibArticle</td><td>Sarkadi B, Ozvegy-Laczka C, Nemet K, Varadi A, ABCG2-a transporter for all seasons.<Emphasis Type="Italic">FEBS Lett</Emphasis>. 2004;567:116&#8211;120.</td><td><a href=http://dx.doi.org/10.1016/j.febslet.2004.03.123>10.1016/j.febslet.2004.03.123</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR133</td><td>BibArticle</td><td>Bunting KD. ABC transporters as phenotypic markers and functional regulators of stem cells.<Emphasis Type="Italic">Stem Cells</Emphasis>. 2002;20:11&#8211;20.</td><td><a href=http://dx.doi.org/10.1634/stemcells.20-3-274>10.1634/stemcells.20-3-274</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR134</td><td>BibArticle</td><td>Abbott BL. ABCG2 (BCRP) expression in normal and malignant hematopoietic cells.<Emphasis Type="Italic">Hematol Oncol</Emphasis>. 2003;21:115&#8211;130.</td><td><a href=http://dx.doi.org/10.1002/hon.714>10.1002/hon.714</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR135</td><td>BibArticle</td><td>Taipalensuu J, Tornblom H, Lindberg G, et al. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2001;299:164&#8211;170.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR136</td><td>BibArticle</td><td>Cooray HC, Blackmore CG, Maskell L, Barrand MA. Localisation of breast cancer resistance protein in microvessel endothelium of human brain.<Emphasis Type="Italic">Neuroreport</Emphasis>. 2002;13:2059&#8211;2063.</td><td><a href=http://dx.doi.org/10.1097/00001756-200211150-00014>10.1097/00001756-200211150-00014</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR137</td><td>BibArticle</td><td>Zhang W, Mojsilovic-Petrovic J, Andrade MF, Zhang H, Ball M, Stanimirovic DB. The expression and functional characterization of ABCG2 in brain endothelial cells and vessels.<Emphasis Type="Italic">FASEB J</Emphasis>. 2003;17:2085&#8211;2087.</td><td><a href=http://dx.doi.org/10.1096/fj.02-1131fje>10.1096/fj.02-1131fje</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Year, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR138</td><td>BibArticle</td><td>Troger U, Stotzel B, Martens-Lobenhoffer J, Gollnick H, Meyer FP. Drug points: severe myalgia from an interaction between treatments with pantoprazole and methotrexate.<Emphasis Type="Italic">BMJ</Emphasis>. 2002;324:1497.</td><td><a href=http://dx.doi.org/10.1136/bmj.324.7352.1497>10.1136/bmj.324.7352.1497</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR139</td><td>BibArticle</td><td>Mizuno N, Suzuki M, Kusuhara H, et al. Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice.<Emphasis Type="Italic">Drug Metab Dispos</Emphasis>. 2004;32:898&#8211;901.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR140</td><td>BibArticle</td><td>Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM. Expression, up-regulation, and transport activity of the multidrug-resistance protein abcg2 at the mouse blood-brain barrier.<Emphasis Type="Italic">Cancer Res</Emphasis>. 2004;64:3296&#8211;3301.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-03-2033>10.1158/0008-5472.CAN-03-2033</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>